Resumen de acción TEVA N Teva Pharmaceutical Industries Limited desarrolla, fabrica, comercializa y distribuye medicamentos genéricos, medicamentos especializados y productos biofarmacéuticos en Norteamérica, Europa, Israel y a escala internacional. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Teva Pharmaceutical Industries Limited Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Teva Pharmaceutical Industries Precios históricos de las acciones Precio actual de la acción US$437.01 Máximo en las últimas 52 semanas US$437.01 Mínimo de 52 semanas US$188.00 Beta 0.80 Cambio en 1 mes 19.73% Variación en 3 meses 28.72% Cambio de 1 año 136.22% Variación en 3 años 142.78% Variación en 5 años 131.23% Variación desde la OPV -24.22%
Noticias y actualizaciones recientes
Teva Pharmaceutical Industries Limited to Report Q4, 2024 Results on Jan 29, 2025 Dec 21
Third quarter 2024 earnings released: US$0.39 loss per share (vs US$0.071 profit in 3Q 2023) Nov 08
Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024 Nov 04
Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn) Oct 22
Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024 Oct 01
Second quarter 2024 earnings released: US$0.75 loss per share (vs US$0.77 loss in 2Q 2023) Aug 01 Ver más actualizaciones
Teva Pharmaceutical Industries Limited to Report Q4, 2024 Results on Jan 29, 2025 Dec 21
Third quarter 2024 earnings released: US$0.39 loss per share (vs US$0.071 profit in 3Q 2023) Nov 08
Teva Pharmaceuticals Limited Unveils New Phase 3 Positive Results for Olanzapine Lai, and Presents Real-World Data on Uzedy At Psych Congress 2024 Nov 04
Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn) Oct 22
Teva Pharmaceutical Industries Limited to Report Q3, 2024 Results on Nov 06, 2024 Oct 01
Second quarter 2024 earnings released: US$0.75 loss per share (vs US$0.77 loss in 2Q 2023) Aug 01 Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease Jul 25
Teva Pharmaceutical Industries Limited Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (fremanezumab) Space Trial for Prevention of Episodic Migraine Jul 18
Teva Pharmaceutical Industries Limited to Report Q2, 2024 Results on Jul 31, 2024 Jul 04
Teva Pharmaceutical Industries Ltd Announces New AJOVY® (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses Jun 29
Teva Pharmaceutical Industries Limited Announces Launch of Authorized Generic of Victoza® (Liraglutide Injection 1.8Mg), in the United States Jun 25
Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) May 30
Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024 May 16
First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1Q 2023) May 09 Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024 Teva Pharmaceutical Industries Limited, Annual General Meeting, Jun 06, 2024
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China Apr 11
Teva Pharmaceutical Industries Limited to Report Q1, 2024 Results on May 08, 2024 Apr 10
Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023 Feb 01
Full year 2023 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2022) Feb 01
Teva Pharmaceutical Industries Limited Announces Earnings Guidance for Full Year 2024 Jan 31
Court for the District of New Jersey Issues A Decision That Teva Pharmaceuticals Does Not Infringe Any Asserted Claims of Corcept Therapeutics Incorporated’s U.S. Patents Jan 02
Teva Pharmaceutical Industries Limited Announces Post Hoc Phase 3 Data Analysis Shows AJOVY (Fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-Morbid Obesity Dec 06
Third quarter 2023 earnings released: EPS: US$0.071 (vs US$0.05 in 3Q 2022) Nov 15
Teva Pharmaceutical Industries Ltd. Appoints R. Ananthanarayanan (Ananth) as CEO of Its Teva Active Pharmaceutical Ingredients Business Nov 08
Teva Pharmaceutical Industries Limited Announces Phase IV Unite Study Shows Ajovy® (Fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder Oct 17
Teva Pharmaceutical Industries Limited to Report Q3, 2023 Results on Nov 08, 2023 Oct 07
Teva Announces Changes to Executive Management Team Sep 29
Teva Pharmaceutical Industries Limited Appoints Varda Shalev as Member of the Board, Effective September 1, 2023 Aug 05
Second quarter 2023 earnings released: US$0.77 loss per share (vs US$0.21 loss in 2Q 2022) Aug 05 Teva Pharmaceutical Industries Limited Reports Impairment Charges for the Second Quarter Ended June 30, 2023
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development, Effective August 1, 2023 Jul 28 Teva Pharmaceutical Industries Limited to Report Q2, 2023 Results on Aug 02, 2023
Teva Pharmaceutical Industries Ltd. Announces Further Positive Data from the Pan-European Research Study Jul 01
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY Jun 17
Teva Pharmaceuticals Presents Real-World Data for Austedo (Deutetrabenazine) Tablets with 4-Week Patient Titration Kit At Psych Congress Elevate 2023 Jun 03
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting May 21
Teva Pharmaceutical Industries Limited Announces That Once-Daily Austedoxr (Deutetrabenazine) Extended-Release Tablets Are Now Available for Adults in the United States May 16
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2023 May 11
First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.86 loss in 1Q 2022) May 11
Full year 2022 earnings released: US$2.12 loss per share (vs US$0.38 profit in FY 2021) Feb 09
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2023 Feb 09
Teva Pharmaceutical Industries Limited to Report Q4, 2022 Results on Feb 08, 2023 Jan 13
Karo Pharma AB (publ) agreed to acquire of Six brands of Teva for DKK 84 million. Dec 06 Teva Pharmaceutical Industries Limited Appoints Richard Francis as President, Effective January 1, 2023
Third quarter 2022 earnings released: EPS: US$0.05 (vs US$0.27 in 3Q 2021) Nov 05 Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Year 2022
Teva Pharmaceutical Industries Limited Reaches Agreement with Arkansas to Settle the State’s Price Fixing Claims Oct 08 Teva Pharmaceutical Industries Limited to Report Q3, 2022 Results on Nov 03, 2022 Teva Pharmaceutical Industries Limited Presents Studies of Effectiveness of AJOVY for Treatment of Migraine in Patients with Co-morbid Depression
Exelixis, Inc. Files Complaint in the United States District Court for the District of Delaware for Patent Infringement against Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc Sep 03
Teva Pharmaceutical Industries Limited Announces European Commission Grants Marketing Authorization for Ranivisio (Ranibizumab), for Age-Related Macular Degeneration (AMD) the Most Common Cause of Blindness in Developed Countries Aug 29
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022 Jul 29
Teva Pharmaceutical Industries Limited Announces Impairment Charges for the Second Quarter Ended June 30, 2022 Jul 28
Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.19 profit in 2Q 2021) Jul 27
Teva Pharmaceutical Industries Limited Appoints Eric A. Hughes as Executive Vice President, Global R&D and Chief Medical Officer Jul 02
Teva Pharmaceutical Industries Limited to Report Q2, 2022 Results on Jul 27, 2022 Jun 30 Teva Pharmaceutical Industries Limited Welcomes the UK Medicines & Healthcare Regulatory Agency Decision to Grant A Licence for Ongavia May 18
Teva Pharmaceutical Industries Limited Revises Earnings Guidance for the Full Year 2022
First quarter 2022 earnings released: US$0.86 loss per share (vs US$0.07 profit in 1Q 2021) May 03
Teva Pharmaceutical Industries Limited to Report Q1, 2022 Results on May 03, 2022 Apr 05
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 11
Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year 2022 Feb 10
Investor sentiment improved over the past week Jan 11
Teva Announces Launch of First-To-Market Generic Version of Narcan (Naloxone Hydrochloride Nasal Spray), in the U.S Dec 23
Chief Accounting Officer Andrew Weil has left the company Dec 01
Third quarter 2021 earnings released: EPS US$0.27 (vs US$3.97 loss in 3Q 2020) Oct 29
Teva Pharmaceutical Industries Limited Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims Oct 01
Forecast to breakeven in 2021 Sep 23
Insufficient new directors Aug 19
Independent Director Abbas Hussain has left the company Jul 15
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults Jun 24
Teva Announces Its Launch of the First Generic Perforomist®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States Jun 23 Teva Pharmaceutical Industries Ltd. Presents Analysis on AJOVY® (fremanezumab) Injection
Executive Vice President of International Markets Commercial Gianfranco Nazzi has left the company May 01
Teva Pharmaceutical Industries Limited Announces the Launch of the First Generic Version of Absorica (Isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States Apr 30
First quarter 2021 earnings released: EPS US$0.07 (vs US$0.063 in 1Q 2020) Apr 29
Teva Pharmaceutical Industries Limited Reaffirms Its Earnings Guidance for the Year 2021 Apr 29
Teva to Present New Analyses of AUSTEDO (deutetrabenazine) Tablets and Assessment of Schizophrenia Clinical Outcomes at Upcoming 2021 American Psychiatric Association Annual Meeting Apr 28
Slater Vecchio LLP Files Lawsuit Against Elmiron Manufacturers After Link with Vision Loss Mar 07
Teva Pharmaceutical Industries Limited Announces New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments Feb 27
Full year 2020 earnings released: US$3.64 loss per share (vs US$0.92 loss in FY 2019) Feb 12
Revenue beats expectations Feb 12 Rentabilidad de los accionistas TEVA N MX Pharmaceuticals Mercado MX 7D 0% -1.8% 0.4% 1Y 136.2% -26.7% -11.8%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: TEVA N superó a la industria MX Pharmaceuticals, que obtuvo un rendimiento del -26.7% el año pasado.
Rentabilidad vs. Mercado: TEVA N superó al mercado MX, que obtuvo un rendimiento del -11.8% el año pasado.
Volatilidad de los precios Is TEVA N's price volatile compared to industry and market? TEVA N volatility TEVA N Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 6.3% Market Average Movement 4.1% 10% most volatile stocks in MX Market 6.1% 10% least volatile stocks in MX Market 2.8%
Precio estable de las acciones: El precio de las acciones de TEVA N ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de TEVA N en el último año.
Acerca de la empresa Teva Pharmaceutical Industries Limited desarrolla, fabrica, comercializa y distribuye medicamentos genéricos, medicamentos especializados y productos biofarmacéuticos en Norteamérica, Europa, Israel y a escala internacional. Ofrece medicamentos genéricos en diversas formas farmacéuticas, como comprimidos, cápsulas, inyectables, inhalantes, líquidos, parches transdérmicos, pomadas y cremas; productos estériles, hormonas, medicamentos de alta potencia y sustancias citotóxicas en formas farmacéuticas parenterales y sólidas; y productos genéricos con dispositivos médicos y productos combinados. La empresa se centra en las áreas del sistema nervioso central (SNC), respiratorio y oncología.
Mostrar más Resumen de fundamentos de Teva Pharmaceutical Industries Limited ¿Cómo se comparan los beneficios e ingresos de Teva Pharmaceutical Industries con su capitalización de mercado? Estadísticas fundamentales de TEVA N Capitalización bursátil Mex$497.80b Beneficios(TTM ) -Mex$19.75b Ingresos (TTM ) Mex$345.48b
1.4x Ratio precio-ventas (PS)
-25.2x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de TEVA N Ingresos US$16.77b Coste de los ingresos US$8.41b Beneficio bruto US$8.36b Otros gastos US$9.32b Beneficios -US$959.00m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
Jan 29, 2025
Beneficios por acción (BPA) -0.85 Margen bruto 49.84% Margen de beneficio neto -5.72% Ratio deuda/patrimonio 297.3%
¿Cómo se ha desempeñado TEVA N a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/01/03 06:13 Precio de las acciones al final del día 2024/12/23 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Teva Pharmaceutical Industries Limited está cubierta por 59 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Jasper Hellweg Argus Research Company Balaji Prasad Barclays Richard Silver Barclays
Mostrar 56 más analistas 
